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Selective neuronal loss is the hallmark of neuro-
degenerative diseases. In patients with amyotrophic
lateral sclerosis (ALS), most motor neurons die but
those innervating extraocular, pelvic sphincter, and
slow limb muscles exhibit selective resistance. We
identified 18 genes that show >10-fold differential
expression between resistant and vulnerable motor
neurons. One of these, matrix metalloproteinase-9
(MMP-9), is expressed only by fast motor neurons,
which are selectively vulnerable. In ALS model mice
expressing mutant superoxide dismutase (SOD1),
reduction of MMP-9 function using gene ablation,
viral gene therapy, or pharmacological inhibition
significantly delayed muscle denervation. In the
presence of mutant SOD1, MMP-9 expressed by
fast motor neurons themselves enhances activation
of ER stress and is sufficient to trigger axonal die-
back. These findings define MMP-9 as a candidate
therapeutic target for ALS. The molecular basis of
neuronal diversity thus provides significant insights
into mechanisms of selective vulnerability to neuro-
degeneration.
INTRODUCTION
All neurodegenerative diseases are characterized by neuronal
dysfunction and cell death, which lead to incurable and often
fatal functional deficits (Saxena and Caroni, 2011). However,
the neuronal populations that degenerate are specific to each
disease and it is the selective loss of the corresponding neuronal
function that defines the clinical phenotype. This selective
vulnerability manifests itself at multiple levels. Typically, in a
given disease a single neuronal class is principally affected.
Additionally, however, within this class different regional sub-
populations or functional subtypes degenerate to widely varying
degrees. The fact that most disease-triggering mutant proteinsare expressed ubiquitously suggests that the specificity of
degeneration reflects intrinsic differences between different
neuronal subpopulations. Identifying the molecular basis of
selective vulnerability has the potential to identify novel thera-
peutic targets, which are currently lacking for most neurodegen-
erative diseases.
The uniformly fatal disease amyotrophic lateral sclerosis (ALS)
provides examples of neuronal specificity at every level. First,
motor neurons in the spinal cord, brainstem, and cortex are
selectively lost as compared to other neuronal classes (Cleve-
land and Rothstein, 2001). Second, individual motor pools
(groups of motor neurons innervating single muscles) show
widely varying degrees of disease resistance: in the final stages
of ALS, nearly all voluntary movement is lost but eye movement
and eliminative and sexual functions remain relatively unim-
paired (reviewed in Kanning et al., 2010). These functions are
controlled by motor neurons of the oculomotor (III), trochlear
(IV), and abducens (VI) nuclei in the midbrain and brainstem,
and by Onuf’s nucleus in the lumbosacral spinal cord, respec-
tively. Correspondingly, in ALS autopsies the oculomotor and
Onuf’s nuclei are almost completely preserved (Iwata and
Hirano, 1978; Mannen et al., 1977; Schrøder and Reske-Nielsen,
1984). A third level of specificity is that, even within a givenmotor
pool, certain functional subtypes of motor neuron are more
vulnerable than others. Depending on their contractile proper-
ties, motor units are classified as fast fatigable (FF),
fast-fatigue-resistant (FR), or slow (S). FF motor neurons are
the largest and are involved in short-lasting bouts of forceful
contraction, whereas S motor neurons are smaller and fire regu-
larly to control postural muscles (Kanning et al., 2010). In ALS, S
motor neurons are more resistant and undergo axonal degener-
ation only at later stages, whereas FF motor neurons are the
most vulnerable (Fischer et al., 2004; Frey et al., 2000; Pun
et al., 2006). This is at least in part due to the low excitability of
FF motor neurons (Saxena et al., 2013). However, the molecular
basis of the selective vulnerability of fast motor neurons with
respect to slow spinal motor neurons or those in the oculomotor
and Onuf’s nuclei remains to be determined.
Many studies of ALS disease mechanisms have used trans-
genic mouse models which express mutant forms of superoxide
dismutase (SOD1) that cause familial ALS in humans. In theseNeuron 81, 333–348, January 22, 2014 ª2014 Elsevier Inc. 333
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forms of the disease, selective resistance of S motor units and
preservation of extraocular muscle innervation are observed
(Pun et al., 2006; Valdez et al., 2012). This is despite ubiquitous
expression of mSOD1 at high levels in multiple cell types known
to be involved in disease onset and progression, including astro-
cytes, microglia, and motor neurons themselves (Ilieva et al.,
2009). Multiple mechanisms of motor neuron degeneration trig-
gered by mSOD1 have been proposed. Among these, early acti-
vation of endoplasmic reticulum (ER) stress in FF motor neurons
correlates with their axonal degeneration, and inhibition of ER
stress using salubrinal, which prevents dephosphorylation of
eukaryotic initiation factor-2a (EIF2a), delays muscle denerva-
tion and leads to an increase in lifespan (Saxena et al., 2009).
The preferential activation of the ER stress response in FF motor
neurons seems to be triggered as a result of their reduced excit-
ability (Saxena et al., 2013), but the molecular links between
these functional characteristics and ER stress are not well under-
stood. More generally, although some molecular differences
between oculomotor and other motor neurons, or between large
and small spinal motor neurons, have been reported (Alexianu
et al., 1994; Aronica et al., 2001; Brockington et al., 2013;
Hedlund et al., 2010; Laslo et al., 2000; Sasaki et al., 2006; Van
Hoecke et al., 2012), themolecular basis of ALS resistance in vivo
remains to be determined.
There are therefore at least two aspects of differential motor
neuron vulnerability in ALS: a pool-specific resistance typified
by oculomotor and Onuf’s nuclei, and a subtype-specific vulner-
ability of FF as compared to S motor units. We focused first on
the former and used microarray profiling of isolated wild-type
motor neurons to identify genes whose expression was charac-
teristic of both oculomotor and Onuf’s nuclei but not of vulner-
able lumbar spinal neurons, or vice versa. One such gene, matrix
metalloproteinase-9 (MMP-9), while strongly expressed by a
majority of cranial and spinal motor neurons, was absent from
oculomotor and Onuf’s nuclei. Strikingly, it was also undetect-
able in S motor neurons in the spinal cord. This identifies
MMP-9 as a prospective marker for all ALS-vulnerable motor
neurons, in which it is first detected immediately prior to the
earliest known functional changes in the neonatal spinal cord.
Functionally, even partial reduction of MMP-9 levels in mSOD1
mice leads to pronounced delays in muscle denervation and a
significant extension of lifespan. Moreover, MMP-9 acts early
in the disease process, facilitating the onset of subtype-specific
ER stress. Our data therefore identify MMP-9 as a strong candi-
date therapeutic target for ALS and substantiate this general
approach for other neurodegenerative diseases in which loss
of specific neuronal subpopulations is observed.
RESULTS
Identification of Candidate ALS Resistance and
Susceptibility Genes
In order to identify molecular characteristics that contribute to
selective vulnerability in ALS, we focused first on pool-specific
resistance as typified by oculomotor and Onuf’s (referred to as
dorsolateral [DL] nucleus in mouse) nuclei (Figure S1A available
online). We performed microarray profiling of motor neurons334 Neuron 81, 333–348, January 22, 2014 ª2014 Elsevier Inc.laser-captured from sections of brain and spinal cord of wild-
type mice at P7 (Figures 1A and S1B). Wild-type mice were
used because we wished to identify intrinsic properties of resis-
tance rather than disease responses, and P7 corresponds to a
stage at which developmental cell death is complete and the first
functional abnormalities in the spinal cord of mSOD1 mice are
observed (Bories et al., 2007). Pairwise sample comparisons
among the three motor neuron subpopulations revealed 66–
131 genes that exhibited >10-fold differences in expression
levels (Figure 1A). Lowering the threshold to 5-fold identified
>200 differentially expressed genes (Figures 1B, S1F, and
S1G). This molecular heterogeneity of postnatal motor neurons
likely reflects their widely divergent functions.
We considered that the four genes expressed at >10-fold
higher levels in both resistant populations than in vulnerable L5
motor neurons had a higher chance of representing ALS
resistance genes (Figure 1A, red), whereas the 14 genes ex-
pressed only in vulnerable motor neurons might be ALS suscep-
tibility genes (Figure 1A, green). For nine of them (asterisks in
Table S1), we validated the microarray data by in situ hybridiza-
tion (ISH) on sections of P7 hindbrain and spinal cord, using
retrograde labeling from the ischiocavernosus (IC) muscle to
identify the DL nucleus (examples in Figure 1D). These 18 genes
have known functions that are highly diverse but have in most
cases never been linked to ALS or neurodegenerative disease
(Table S1).
This gene list represents a valuable resource for future studies
of selective neuronal resistance. To prioritize genes for initial
study, we considered that the most interesting candidates for
therapeutic intervention in this late-onset disease would show
strong, motor-neuron-specific expression throughout postnatal
and adult life. Only Hsd17b2 and Mmp9 fit these criteria (Fig-
ure 1C). SinceMmp9 did not rank above no. 24 on either pairwise
comparison, we reasoned it had the greatest chance of being
linked to ALS rather than to specific properties of either pool.
Moreover, given early interest from the cancer field (Swarnakar
et al., 2012) and the fact that potential (though controversial) links
between MMP-9 and ALS had been reported (Dewil et al., 2005;
He et al., 2013; Kiaei et al., 2007; Lorenzl et al., 2003, 2006; Swar-
nakar et al., 2012), there was a wide range of reagents available.
MMP-9 Is Selectively Expressed by Vulnerable Motor
Neurons
Levels ofMmp9mRNAwere 16-fold lower in oculomotor than L5
motor neurons and 11-fold lower in DL (Figures 1C and 1D). In
the spinal cord, strong MMP-9 expression is specific to motor
neurons (Figure 2A). It is first detected only postnatally at P5
but subsequently remains expressed at high levels until the latest
time point studied, P165 (Figures 2B–2F). At the protein level,
using an MMP-9 antibody that gave no signal inMmp9 knockout
mice (Figure S4H), MMP-9 was not detected in any of the three
cranial nuclei (III, IV, and VI) that innervate extraocular muscles
or in the ventrolateral region of the DL nucleus in the L6 spinal
cord that innervates the external urethral sphincter (Figures
2G–2I and 2L). In contrast, motor neurons expressing high levels
ofMMP-9were abundant in trigeminal and facial nuclei aswell as
in L5-L6 spinal motor neurons (Figures 2J and 2K; data
not shown). Therefore, MMP-9 is absent from ALS-resistant
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Figure 1. Identification of Candidate ALS
Resistance and Susceptibility Genes by
Gene Profiling of Laser-Captured Motor
Neurons
(A) Gene expression profiles of mouse lumbar
motor neurons (L5), oculomotor nucleus (III; pink),
and Onuf’s nucleus (DL; blue) overlap but also
reveal significant differences between motor
neuron populations. Figures indicate number of
genes expressed at >10-fold higher levels in each
subset (p < 0.05). ALS resistance genes are more
likely to be found among genes enriched in both III
and DL (red), while susceptibility genes (dark
green) are predicted to be enriched in L5.
(B) Numbers of genes showing significant differ-
ences (p < 0.05 by one-way ANOVA) among the
three populations at different fold ratios.
(C) Identities of 18 genes enriched (red) or
depleted (green) in the two resistant populations
showing fold changes for three replicates. The +
signs in the P7 ISH column indicate levels of ISH in
motor neurons;  signs indicate no detectable
expression. For P57, +++ indicates differential
expression maintained at comparable levels to
P7, ++ indicates more restricted expression, and +
indicates low levels.
(D) Sample validation of microarray data by ISH for
indicated genes in P7 midbrain and lumbar spinal
cord. At L6, DL (Onuf’s) nucleus motor neurons
were identified by injection of CTB (red) into the IC
muscle at P5. Resistant motor neurons do not
express Mmp9 or Hsd17b2. Scale bar, 20 mm.
See also Figure S1 and Table S1.
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MMP-9 Drives Loss of Fast Motor Neurons in ALSpopulations in midbrain and spinal cord but is present in many
other motor neurons.
Even within motor neuron populations that expressedMMP-9,
labeled cells were intermingled with MMP-9-negative neurons
(Figures 2J–2L and S3B), suggesting that MMP-9 might be a
finer-grainedmarker of vulnerability. For a series ofmotor neuron
subpopulations, we therefore compared the percentage of
motor neurons lost at end-stage in SOD1G93A mice (our data
and Ferrucci et al., 2010) to the fraction that expressed MMP-9
in wild-type mice (Figure 2M). Absolute values in the two data
sets showed remarkably strong positive correlation (R2 > 0.96),
suggesting that motor neurons that express MMP-9 are those
subsequently lost in ALS.
To test this prediction, we examined MMP-9 staining in
SOD1G93A mice. At presymptomatic stages up to P40, levels
and localization of MMP-9 were indistinguishable from wild-
type (Figures S2A and S2C). Mutant SOD1 does not therefore
itself trigger misexpression of the enzyme. At end-stage, in strik-
ing contrast, although MMP-9 could be detected in microglia
(Figure 2P), all 50% of motor neurons that remained were
MMP-9 negative (compare Figures 2N and 2O). This suggested
that MMP-9-expressing motor neurons are selectively lost
during the ALS disease process. An alternative explanation
was that motor neurons downregulate MMP-9 prior to their
death, and we indeed detected a small but significant increase
in the numbers of MMP-9-negative motor neurons at intermedi-
ate stages (Figure S2N). However, the absolute number ofsurviving motor neurons in L5 spinal cord at end-stage was
indistinguishable from the number of MMP-9-negative cells
initially present (Figure 2Q; p = 0.62, t test). Thus, MMP-9 is a
prospective marker for vulnerable motor neurons in this mouse
model of ALS.
MMP-9 Is Selectively Expressed by Fast Motor Neurons
Since die-back of axons of FF motor units precedes that of FR
and S (Pun et al., 2006), we asked whether the MMP-9-express-
ing neurons might be fast motor neurons. A first characteristic of
FF/FRmotor neurons is that they are larger than Smotor neurons
(Cullheim et al., 1987). Limiting our analysis to a-motor neurons
by costaining for NeuN (Friese et al., 2009; Shneider et al.,
2009), we observed that motor neurons with the highest intensity
of staining for MMP-9 were the largest (Figures 3A and S3). As a
second criterion, we identified motor neurons of the slow soleus
(Sol) and fast tibialis anterior (TA) pools by injection of retrograde
tracer into eachmuscle in adult mice (Figures 3B–3G). The abso-
lute values for MMP-9+ andMMP-9-negative abundance among
labeled motor neurons closely matched the percentage of fast
and slow fiber types previously reported in Sol (53% MMP-9+;
54% FF+FR) and TA (90% MMP-9+; 93% FF+FR) muscles (Fig-
ure 3H; Hegedus et al., 2007). Lastly, we compared the expres-
sion of MMP-9 with that of chondrolectin (Chodl), reported to be
amarker of fast motor neurons (Enjin et al., 2010), using aChodl-
LacZ mouse that selectively labels a subset of motor neurons
(Figure 3I). Of all MMP-9+ motor neurons, 96% also expressedNeuron 81, 333–348, January 22, 2014 ª2014 Elsevier Inc. 335
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Figure 2. MMP-9 Is a Prospective Marker for Motor Neurons Lost at End-Stage in ALS Model Mice
(A) In P25 SOD1G93A mouse lumbar spinal cord, intense MMP-9 immunostaining is restricted to motor neurons, though some dorsal neurons stained weakly
(arrow). Scale bar, 100 mm.
(legend continued on next page)
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MMP-9 Drives Loss of Fast Motor Neurons in ALSthe Chodl-LacZ/+ reporter, and only 29% of LacZ+ cells lacked
MMP-9 (Figures 3I and 3J). Overall, therefore, MMP-9 is selec-
tively expressed in fast a-motor neurons, and these are the
neurons destined to die in ALS mice. No markers to distinguish
FF and FR motor neurons exist in rodents. However, we hypo-
thesize that the population that shows intermediate size and
lower levels of MMP-9 (Figure 3A) corresponds to FR motor
neurons.
Motor Neurons Innervating Extraocular Muscles and
Lumbar Sphincters Are Also Resistant in ALS Model
Mice
As a condition for testing the functional contribution of MMP-9 to
degeneration in ALS, we needed to ascertain the pattern of
selective resistance in SOD1G93A mice at end-stage. As shown
by Pun et al. (2006), the fast TA muscle showed nearly complete
denervation, whereas the slow Sol retained significantly more
innervation (Figures 4A, 4C, and 4E). The extraocular muscles
were recently reported to be collectively resistant (Valdez
et al., 2012), so we examined them individually (Figure 4E). All
eight extraocular muscles showed nearly complete resistance,
as did the pelvic sphincters, external urethral sphincter (EUS),
and external anal sphincter (EAS). This remarkable overlap be-
tween the selectivity of muscle denervation in the SOD1G93A
mouse and that in human patients with sporadic ALS strongly
suggests the existence of shared mechanisms of vulnerability.
MMP-9 Is Required for Muscle Denervation during the
ALS Disease Process
We therefore bred Mmp9/ mice to SOD1G93A mice, both on a
pure C57BL/6 background. MMP-9 knockout mice are healthy
and have a normal lifespan (Vu et al., 1998). Although they
have been reported to show mild cognitive deficits, we found
no muscle denervation or motor behavioral phenotype at any
stage as compared to wild-type controls (data not shown). We
first confirmed that axonal die-back occurred much earlier in
the fast TA muscle (Figures 5A, 5B, and 5G) than in the slow
Sol muscle (Figures 5C and 5H; Pun et al., 2006).
We next analyzed muscle denervation in SOD1G93A mice lack-
ing MMP-9. Remarkably, at P50 in the TA muscle of
SOD1G93A;Mmp9/ mice, no denervation was detected and,
even at P100, more than 75% of motor endplates remained
innervated, representing a 2.5-fold improvement over mSOD1
controls (Figures 5D, 5E, and 5G). Significant protection was
also observed in the slow Sol muscle (Figures 5F and 5H). These
strong protective effects did not reflect altered mSOD1 levels,
since neither transgene copy number nor protein levels were(B–F) MMP-9 is first detected by ISH in nontransgenicmouse lumbar spinal cord p
P165 (F).
(G–L) Immunostaining for MMP-9 (green) on P30 spinal cord of ChAT-Cre; ROSA-
expressing high levels of MMP-9 in the vulnerable trigeminal nucleus (J), L5 spina
abducens (I), and DL (L) nuclei show no or very little MMP-9 expression. Scale b
(M) Tight correlation between MMP-9 expression in wild-type motor pools and th
R2 > 0.96. Values are mean ± SEM (n = 3).
(N, O, and Q) By end-stage at L5 in SOD1G93A mice, 50% of motor neurons ar
nontransgenic control in (N)). Scale bars, 20 mm.
(P) All MMP-9 expressed in spinal cord at end-stage colocalizes with microglial
See also Figure S2.changed by the removal of MMP-9 (Figures S4B and S4I–S4K).
Therefore, genetic ablation of a single constituent of vulnerable
motor neurons led to a delay of 80 days in loss of innervation
of fast muscles. This >2.5-month retardation in a mouse mutant
that lives for only 6months is the strongest beneficial effect so far
reported in ALS model mice, other than by removing the disease
gene itself (reviewed in Turner and Talbot, 2008).
Strikingly, inactivation of even a single allele of Mmp9 also
conferred significant benefit. MMP-9 levels in heterozygous
SOD1G93A;Mmp9+/ mice were 50% of those in wild-type
mice (Figures S4A and S4C–S4K), but this incomplete reduction
of MMP-9 was sufficient to afford 70% of the protection pro-
vided by complete ablation up to P100 and equivalent protection
at end-stage (Figures 5G and 5H).
To confirm that the preserved synapses were functional, we
measured the compoundmuscle action potential (CMAP; Towne
et al., 2011). By P105–P130, the CMAP in SOD1G93A mice was
reduced to 10% of control values, but deletion of one or two
copies of Mmp9 rescued up to 50% of normal values (Figures
5I and 5J). Similar improvement in other functional tests that
measure late changes in the mSOD1 mice, such as the rotarod
(Figure S4O) and swim (Figure 5K) tests, was also observed.
Motor neuron numbers in the spinal cord initially decreased
more slowly in the absence of Mmp-9 (Figures S4L–S4N). This
protection was transient, however, and by P160 motor neuron
numbers were comparable between the two genotypes. Since
by this stage many SOD1G93A;Mmp9+/+ mice had died whereas
all SOD1G93A;Mmp9/ were still alive, MMP-9 deletion likely
also promotes axonal sprouting and an increase in the average
motor unit size.
Lifespan in mSOD1 mice is determined by the stage at which
mice can no longer right themselves in 30 s. Median survival of
SOD1G93A mice in our C57BL/6 colony was 156 days. This was
increased to 178 days by removal of a single allele of Mmp9
and to 195 days by complete ablation, representing a 25%
increase in lifespan (Figure 5L). Our survival data are comparable
to those reported by Kiaei et al. (2007) (see Discussion) on a
mixed background. The systemic benefit of MMP-9 deletion is
clearly apparent from visual inspection of three male SOD1G93A
littermate mice bearing two, one, and zero copies of Mmp9 at
P150 (Movie S1): even Mmp9 heterozygotes show major im-
provements in their ability to grasp bars and right themselves.
MMP-9 Enhances Activation of ER Stress in ALS Motor
Neurons
To determine the interactions between MMP-9 and the disease
pathway as currently understood, we focused on the unfoldedostnatally at P5 (C), and remains at high levels until the latest time point studied,
TdTomato (motor neuron [MN], red) reporter mice shows many motor neurons
l cord (K), and RDL in L6 (L). In contrast, resistant oculomotor (G), trochlear (H),
ars, 20 mm.
eir vulnerability to ALS. Absolute values fit a linear regression y = 1.07x + 3.99,
e lost (Q). Of those surviving, all are MMP-9-negative (compare (O) with P40
marker IBA-1. Scale bars, 20 mm.
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Figure 3. MMP-9 Is a Marker for Fast Motor Neurons
(A) a-MNs (ChAT+/NeuN+) expressingMMP-9 are larger, consistent with a fast identity. MMP-9hi andMMP-9lo potentially reflect FF and FR, respectively. Staining
intensity was determined as in Figure S3.
(legend continued on next page)
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Figure 4. Extraocular and Pelvic Sphincter
Motor Units Show Selective Resistance in
ALS Model Mice
(A–D) Overlap of VAChT-positive motor terminals
(green) with acetylcholine receptors stained using
BTX (red) as an indicator of innervated motor
endplates in end-stage SOD1G93A mice. The fast
TA muscle exhibits marked denervation (A),
whereas the slow Sol remains partially innervated
(C). The extraocular muscle superior rectus (SR)
(B) and the EUS (D) show nearly complete pres-
ervation of motor units. Scale bar, 20 mm.
(E) Percentage of intact neuromuscular junctions
in muscles of end-stage SOD1G93A mice (mean ±
SEM from three animals). Control, nontransgenic
values are indicated by the gray-shaded region.
Muscles (top row): levator palpebrae (LP), medial
rectus (MR), inferior rectus (IR), inferior oblique
(IO), retractor bulbi (RB), superior oblique (SO),
lateral rectus (LR), IC, EAS, and bulbocavernosus
(BC). Motor neurons (bottom row): lumbar spinal
cord (L), oculomotor nucleus (III), trochlear nucleus
(IV), abducens nucleus (VI), and dorsolateral and
dorsomedial components of Onuf’s nucleus (DL
and DM).
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MMP-9 Drives Loss of Fast Motor Neurons in ALSprotein response (UPR), one of the earliest molecular events
in SOD1G93A mice (Saxena et al., 2009), as detected by
phosphorylation of EIF-2a (P-EIF2a). When we quantified the
overlap of P-EIF2a and MMP-9 (Figures 6A–6G), the number of(B–G) Many motor neurons of the fast TA pool, identified by retrograde labeling with CTB488 (green), are MM
to be negative. Scale bar, 20 mm.
(H) MMP-9 staining in the TA and Sol motor pools (mean ± SEM; n = 3; left panel) compared to fiber type distri
Hegedus et al. (2007) (right panel). Values for fast fibers are very close to those for MMP-9+.
(I and J) Immunostaining for VAChT (blue), MMP-9 (green), and b-galactosidase (red) on spinal cord of an
between MMP-9 and the Chodl reporter.
(K) In SOD1G93A;Mmp9+/+mice, denervation of the superficial, skin-facing compartment (black) precedes tha
(p = 0.039).
(L) The two subcompartments of the TA become denervated at an identical rate in SOD1G93A;Mmp9/ mic
See also Figure S3.
Neuron 81, 333–348double-labeled cells was significantly
greater than expected by chance (p <
0.01, t test). Therefore, ER stress and
UPR are selectively induced in MMP-9+
motor neurons, in agreement with
their FF/FR identity. Strikingly, at P40
in SOD1G93A mice that were null for
Mmp9, only <25% of the normal number
of motor neurons stained for P-EIF2a,
and this fraction was even lower
at P50 (Figures 6H–6N). At later
stages, P-EIF2a levels increased even
in SOD1G93A;Mmp9/ mice (data not
shown), suggesting that Mmp9 deletion
delays, but does not indefinitely prevent,
the onset of ER stress. Thus MMP-9 is
necessary for normal activation of the
earliest known biochemical event trig-
gered by mSOD1.Later onset of ER stress is a characteristic of resistant S
motorneurons (Saxenaetal., 2009), soweaskedwhetherablating
MMP-9 leadsmotor neurons to adopt amoreS-like phenotype. In
SOD1G93Amice, denervation of the ‘‘skin-facing’’ compartment ofP-9-positive (red), whereas Sol motor neurons tend
bution in the corresponding muscles replotted from
adult Chodl-lacZ mouse. There is strong overlap
t of the deep, bone-facing fibers (blue) by >20 days
e (p = 0.560).
, January 22, 2014 ª2014 Elsevier Inc. 339
Figure 5. Genetic Ablation of MMP-9 Markedly Delays Muscle Denervation and Loss of Motor Function in SOD1G93A Mice
(A–F) Mmp9 deletion in SOD1G93A delays loss of muscle innervation in both TA and Sol muscles. Scale bars, 20 mm.
(G–L) Morphological and functional evaluation of four different genotypes, color-coded in the same way in all panels: SOD1G93A;Mmp9+/+ (black; +/+),
SOD1G93A;Mmp9+/ (blue; +/), SOD1G93A;Mmp9/ (red; /), and nontransgenic (gray; WT). Denervation of TA muscle is delayed by 80 days by removal of
(legend continued on next page)
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>20days, indicating that the compartments have FF and FRchar-
acter, respectively (Figure 3K; Pun et al., 2006). In contrast, in TA
muscle of SOD1G93A;Mmp9/ mice, the two compartments
became denervated at an identical rate (Figure 3L). Moreover,
the rate of muscle denervation by the ‘‘fast’’ motor neurons of
the TA pool in SOD1G93A;Mmp9/ mice (Figure 5G, red points)
was remarkably similar to that for the mostly slow motor neurons
of the neighboring Sol pool in SOD1G93A mice that had normal
levels of MMP-9 (Figure 5H, black points; Figure S4P). Therefore,
FF and FR motor neurons lacking MMP-9 both adopt an axonal
die-back phenotype comparable to that of S motor neurons.
MMP-9 Is Sufficient to Induce Degeneration in Fast
Motor Neurons of ALS Mice
Since MMP-9 is necessary for normal onset of muscle denerva-
tion, we asked whether it was alone sufficient to trigger axonal
die-back in ALS-resistant motor units. An adeno-associated
virus serotype 6 (AAV6) vector expressing full-length Mmp9
cDNA was injected at P4 into the intraorbital space of SOD1G93A
mice, resulting in stable expression of MMP-9 in a significant
fraction of oculomotor neurons throughout adulthood, at levels
comparable to those in FFmotor neurons (Figures 7A–7D). How-
ever, we detected no increase in denervation of extraocular mus-
cles even at P150 (Figure 7E), and similar results were observed
in the slow Sol muscle (Figures 7C and 7E). Thus, simple coex-
pression of MMP-9 and mSOD1 in a neuron is not sufficient to
trigger its degeneration, suggesting that other elements of the
pathway also need to be present.
Accordingly, when MMP-9 was overexpressed in the fast TA
motor pool of SOD1G93A mice, denervation was further acceler-
ated (Figures 7D and 7E). Moreover, MMP-9 was sufficient to
restore vulnerability to TA motor neurons rendered resistant by
Mmp9 deletion. AAV6-MMP-9 was injected into one TA muscle
of a neonatal SOD1G93A;Mmp9/ mouse, while either no virus
(n = 2) or AAV6-GFP (n = 2) was injected into the contralateral
TA as a control (Figure 7F). By P50, the control muscle remained
fully innervated, whereas 22% of the neuromuscular junctions
(NMJs) became denervated in the injected muscle (Figure 7G).
Overall, therefore, within the cellular context of fast motor neu-
rons expressingmSOD1, the rate of degeneration is proportional
to the level of MMP-9. However, activation of the pathway for
axonal die-back requires neuronal-subtype-specific elements
in addition to MMP-9 and SOD1.
MMP-9 Acts Centrally in Motor Neurons to Drive
Degeneration
To identify the cell type in which MMP-9 is acting to promote
neurodegeneration, we took advantage of the specific target-
ing properties of the AAV6 serotype of adeno-associated viraleither one or both alleles ofMmp9 (G). Denervation of slow Sol muscle is later than
and (H), values are mean ± SEM of one muscle from each of three to four anima
(I and J)MMP-9 ablation significantly rescuesmuscle function. Evoked CMAPs in t
measurements from groups of the indicated genotypes aged between P105 and
(K) Mmp9 deletion significantly delays motor impairment in a swimming task tha
(L) Lifespan is prolonged by 14% following deletion of one Mmp9 allele and b
probability of survival of indicated genotypes (n = 12–19 animals per genotype; l
See also Figure S4 and Movie S1.vectors (Snyder et al., 2011; Towne et al., 2008). When admin-
istered intracerebroventricularly (i.c.v.) in neonatal mice, AAV6
infected 60% of motor neurons throughout the spinal cord
(Figures S5A–S5D), as well as proprioceptive sensory neurons
(data not shown). In contrast, intramuscular (i.m.) injection into
a single skeletal muscle labels only the muscle and corre-
sponding motor pool and proprioceptive neurons (Towne
et al., 2011). Therefore, the only two cell types infected in
common by the i.c.v. and i.m. routes are motor neurons and
proprioceptive neurons. Administration of AAV6 vectors ex-
pressing shRNA to Mmp9 led to partial (20%; p = 0.03) reduc-
tion in numbers of MMP-9+ motor neurons and a stronger
(50%; p = 0.0003) reduction in the MMP-9hi population (Fig-
ures 8B–8F). We observed strong protective effects of post-
natal knockdown of MMP-9 by either route, comparable to
the protection afforded by heterozygote deletion of Mmp-9,
but not following injection of a mismatch control into the
contralateral TA of the same animal (Figures 8G–8I). Since
both i.c.v. and i.m. routes conferred protection, and since pro-
prioceptive neurons do not express MMP-9 even in ALS mice
(Figures S6B–S6E), our results identify mSOD1 motor neurons
as the relevant source of MMP-9 for motor neuron
degeneration.
The genetic approaches used thus far did not distinguish the
relative contributions of the proteolytic enzyme activity of
MMP-9 and the nonenzymatic activity of its hemopexin
domain (Van den Steen et al., 2006; Vandooren et al., 2013).
Moreover, they left open the question of whether MMP-9
acts within the spinal cord or at the neuromuscular junction.
A previous study using a chemical inhibitor of MMPs including
MMP-9 found only modest benefit in mSOD1 mice (Lorenzl
et al., 2006), but this may have reflected insufficient CNS
exposure. A commercially available inhibitor (MMP inhibitor I),
which is among the most potent and specific for MMP-9,
was therefore administered centrally (2 mg i.c.v., daily) to
mSOD1 mice from P55 (the earliest time point at which stereo-
tactic administration is feasible) to P75. The inhibitor caused a
significant delay in TA muscle denervation as compared to
controls (Figure 8J). Moreover, it also reduced levels of ER
stress in the ventral horn of SOD1G93A animals at P75,
compared to vehicle-treated controls (Figures 8K and 8L).
The fact that protection was incomplete may reflect partial
enzyme inhibition in situ and/or a contribution of the non-
enzymatic actions of MMP-9. These results show that
MMP-9 inhibition initiated even after the start of the degener-
ative process can confer significant protection. Moreover,
although we cannot formally exclude leakage of inhibitor to
the periphery, some critical actions of MMP-9 likely occur at
the level of the spinal cord, either directly on fast motor neu-
rons or on neighboring cells and synapses.TA, but is further delayed by 50 days in the absence of MMP-9 (H). For both (G)
ls per genotype (***p < 0.001, **p < 0.01).
he TAmuscle after stimulation of the sciatic nerve. s.a., stimulus artifact. CMAP
P130 (J). Means ± SEM (n = 3–4 animals per genotype); *p < 0.05.
t reflects hindlimb function (n = 10; p = 0.005).
y 25% following deletion of both. Kaplan-Meier plot showing the cumulative
og-rank test = 49.2; p < 0.001).
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Figure 6. MMP-9 Is Required for Early Activation of ER Stress in Fast SOD1G93A Motor Neurons
(A–F) Immunostaining for MMP-9 (green) and ER stress marker phospho-EIF2a (red) in P40 spinal cord of nontransgenic (WT) and SOD1G93A mice. P-EIF2a is
restricted to mSOD1 mice (compare E with B) and colocalizes with MMP-9 (F). Scale bars, 20 mm.
(G) MMP-9-expressing motor neurons preferentially activate ER stress. There are significantly more SOD1G93A motor neurons copositive for P-EIF2a andMMP-9
(yellow) than would be predicted by chance (gray bar).
(H–N) The normal abrupt appearance of P-EIF2a at P40 in SOD1G93A motor neurons is severely damped in the absence of MMP-9. Scale bars, 20 mm. **p < 0.01
compared to P-EIF2a-positive cells in normal mSOD1 mice.
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Figure 7. MMP-9 Is Sufficient to Induce Degeneration in Fast Motor Neurons of ALS Mice
(A) AAV6 expressing full-length mouse MMP-9 under CMV promoter (top panel). Injections into TA or Sol muscles or intraorbitally were performed at P4 (bottom
panel; n = 3–4 animals per genotype; control AAV6-GFP injection on contralateral side).
(B) Immunostaining forMMP-9 (red) of the oculomotor nuclei (ChAT+; green) of a P150 SOD1G93Amouse following intraorbital (extraocularmuscle [EOM]) injection
of AAV6-MMP9.
(C and D) High levels of MMP-9 (white) in (C) Sol (P100) or (D) TA (P50) motor pools following injection of AAV6-MMP9.
(E) Viral expression of MMP-9 is not sufficient to induce denervation in resistant motor pools (Sol or SR) of SOD1G93A mice, but it does accelerate denervation in a
susceptible pool (TA). **p < 0.01
(F) Immunostaining for MMP-9 (white) on a transverse spinal cord section of a P50 SOD1G93A;Mmp9/ mouse injected at P4 with AAV6-MMP9 into its left TA
muscle.
(G) Mmp9 significantly restores vulnerability to the TA muscle (red bar), compared to the control contralateral side (black bar). **p < 0.01
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MMP-9 Drives Loss of Fast Motor Neurons in ALSOverall, these data show that MMP-9 acts in fast motor
neurons to trigger their degeneration and that the disease pro-
cess depends at least in part on the enzymatic activity of MMP-9 within the spinal cord. Moreover, modulation of MMP-9 levels
or activity even at postnatal stages using clinically relevant
modesof intervention cansignificantly delaymuscledenervation.Neuron 81, 333–348, January 22, 2014 ª2014 Elsevier Inc. 343
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Neuronal Diversity and Disease Vulnerability
Our data show that MMP-9 plays a major role in motor neuron
degeneration in ALS model mice. Its expression prior to disease
onset defines the subset of motor neurons that are destined to
die: the fast motor neurons that are also most vulnerable in
human patients. Subsequently, MMP-9 acts in motor neurons
themselves to trigger degeneration and plays an important role
in enabling activation of ER stress, the earliest biochemical event
thus far identified in the disease pathway downstream of
mSOD1. Genetic, viral, or pharmacological inactivation of
MMP-9 each significantly delays the defining cellular event in
the onset of paralysis—denervation of muscle endplates—and
genetic ablation confers significant functional benefit. Our
analysis of molecular diversity within a defined neuronal class
therefore has identified a potential therapeutic target of general
significance for this currently incurable disease.
The strong protection conferred by removal of MMP-9
raises many questions as to its mode of action, the relation of
MMP-9 expression to motor neuron subtype, and the potential
significance of this approach for other neurodegenerative
diseases.
MMP-9 as a Candidate Therapeutic Target
The current lack of effective therapies in ALS reflects the paucity
of therapeutic targets validated in vivo, other than the mSOD1
gene itself (Przedborski, 2004). Our findings designate MMP-9
as a promising candidate for several reasons. First, the
80 day delay in fast muscle denervation is the strongest effect
yet reported in SOD1G93A mice (Turner and Talbot, 2008). Dener-
vation directly affects muscle strength and occurs with similar
specificity in ALS mice and human patients, therefore consti-
tuting a clinically relevant endpoint. Second, removal of MMP-
9 leads to a 25% increase in lifespan, an effect only surpassed
by knockdown of mSOD1 itself (Xia et al., 2006) or transgenic
overexpression of heavy neurofilament subunits, whose mecha-
nism is not understood (Couillard-Despre´s et al., 1998). Third,
MMP-9 appears to act early in the disease pathway triggered
by mSOD1. Fourth, reducing MMP-9 levels appears to be safe,
since small-molecule inhibitors of MMP-9 were tolerated in hu-
mans andMMP-9 null mice show onlymild cognitive phenotypes
and defects in wound healing (Hattori et al., 2009; Nagy et al.,
2006). A final argument for the viability of MMP-9 as a target isFigure 8. Gene Silencing or Central Pharmacological Inhibition of MM
(A) AAV6 expressing H1:shMmp9 and CMV:GFP was injected i.c.v. at P1 or into
(B–E) Reduction of MMP-9 at the single-cell level in P50 wild-type mice following A
colocalization of GFP (green) and NeuN immunostaining (blue), stained for MMP-
GFP+ a-MNs that retain MMP-9 immunoreactivity. Scale bars, 20 mm.
(F) AAV6:shMMP9 (i.c.v.) leads to a 19% reduction in the total number of MMP9
(p = 0.0003).
(G and H) MMP-9 silencing selectively delays muscle denervation in TA muscle.
(I) AAV6-shMmp9 confers similar protection as the heterozygote knockout (dotte
mice following genetic reduction in MMP-9 levels (gray bars; data from Figure 5G
(J) The i.c.v. administration of MMP-9 Inhibitor I daily from P55 to P75 led to incre
n = 5–6 per treatment).
(K and L) Levels of P-EIF2a (white) at P75 in SOD1G93A motor neurons are signifi
See also Figure S5.that even partial reduction in expression levels is sufficient to
confer significant benefit.
These data radically modify our understanding of the role of
MMP-9 in ALS as compared to earlier reports. The first relevant
study found a mild negative effect of MMP-9 deletion on mSOD1
lifespan using the same C57BL/6 background as here (Dewil
et al., 2005), perhaps because of the use of a different Mmp9
knockout strain. This was soon contested by Kiaei et al. (2007)
who, using a mixed genetic background, found survival effects
comparable to those we describe; no other behavioral data
were reported. However, Kiaei et al. (2007) focused on the
MMP-9 expressed late in disease by activated microglia and
deduced that MMP-9 contributes to cytokine-mediated pathol-
ogy in mSOD1 mice. They found that MMP-9 is not expressed
significantly by healthy motor neurons but is upregulated later
in response to mSOD1. In contrast, we find that MMP-9 expres-
sion in motor neurons precedes all known phases of the disease
and that increased MMP-9 levels at late stages are largely in
microglia, not neurons. Our data define MMP-9 as a major early
determinant of ALS pathogenesis, not simply an actor in the
massive degeneration that occurs in the final stages of the
disease.
Although mSOD1 mice lacking MMP-9 do eventually die, indi-
cating that, as expected, other mechanisms also contribute to
degeneration, the strong effect of deletion of a single gene was
striking. MMP-9 is part of a large family of extracellular proteases
that include MMP-2, which digests essentially identical sub-
strates. In other contexts, the effects of MMP-9 inhibition have
been damped or concealed by compensation by other MMPs
(Kru¨ger et al., 2010). The unique expression pattern of MMP-9
provides several potential explanations for its potency in ALS
mice. First, of the 19 family members represented on our micro-
arrays, MMP-9 was the only secreted MMP expressed at high
levels in motor neurons (Figure S6A). Second, only motor neu-
rons and a small population of dorsal interneurons express
MMP-9 in the spinal cord, and few other CNS populations
show strong expression (Figures 2A and S6B–S6E). Third,
thoughMMP-2 is expressed by spinal motor neurons, its expres-
sion is downregulated at the end of embryogenesis before the
start of MMP-9 expression at P5 (Figure 2C) and is not upregu-
lated postnatally in SOD1G93A mice even in the absence of
MMP-9 (Figures S6J–S6M). These results may explain why the
role of MMP-9 in motor neuron degeneration is nonredundant,
a significant advantage for any candidate therapeutic target.P-9 in Motor Neurons Delays Muscle Denervation
TA muscle at P4.
AV6:shMmp9 administration by each route. Transduced a-MNs, visualized by
9 (red). Asterisks, GFP+ a-MNs negative for MMP-9; arrowheads, less frequent
+ motor neurons (*p = 0.03) and a 47% reduction in the numbers of MMP-9hi
d line), whether administered i.c.v. or i.m. TA innervation at P50 in SOD1G93A
) or viral silencing performed i.c.v. (purple) or i.m. (red). Means ± SEM (n = 3–4).
ased innervation in SOD1G93A mice (purple bar) compared to controls (red bar;
cantly reduced by treatment with MMP-9 Inhibitor I.
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Neurodegeneration
Our findings point to an active contribution of MMP-9 to the ALS
disease process. However, MMP-9 is not alone sufficient to
trigger neurodegeneration since it is expressed in many wild-
type motor neurons. Moreover, viral overexpression of MMP-9
in resistant motor neurons did not lead them to degenerate
even in the presence of mSOD1, whereas its expression in
vulnerable fast motor neurons accelerated their degeneration.
MMP-9 therefore seems to selectively condition fast motor neu-
rons to become vulnerable to mSOD1. It will be interesting to
determine the molecular basis of this cell-type-specific function
and whether the presence of MMP-9 is linked to the low excit-
ability of FF motor neurons (Saxena et al., 2013).
Two questions about the selectivity and timing of disease
onset are common to all neurodegenerative disease. The
regional selectivity of neuronal loss might potentially have been
explained by localized expression of the disease triggers them-
selves. Instead, however, disease gene expression is wide-
spread: mSOD1 in the SOD1G93A mouse is expressed in all cells
at levels comparable to those of actin. However, the tightly
restricted expression of MMP-9 in fast motor neurons effectively
gates the onset of disease to this population. Another enigma for
all neurodegenerative diseases is to understand why their symp-
toms start so late. In ALS mice, although mSOD1 is expressed
from early embryonic stages, the first functional and protein mis-
folding changes in vivo are detected only around P7 (Kanning
et al., 2010; Saxena et al., 2013). Strikingly, MMP-9 is not ex-
pressed by embryonic motor neurons and is first detected in
the spinal cord around P5. Therefore, MMP-9 by its develop-
mental regulation and highly localized expression might deter-
mine both the timing and specificity of the disease phenotype.
MMP-9 and Motor Neuron Diversity
Three distinct levels of selectivity of the ALS phenotype had been
identified by earlier studies in mouse and human: preferential
loss of motor neurons as compared to other neuronal classes,
marked resistance of oculomotor and Onuf’s nuclei with respect
to spinalmotor pools, and selective vulnerability of FFmotor neu-
rons over other subtypes. It was a priori possible that there were
different determinants for each level. It is particularly striking that
MMP-9 appears to be relevant to all three distinctions. It is ex-
pressed selectively in motor neurons in the spinal cord, excluded
from oculomotor and Onuf’s nuclei, and absent from the slow,
ALS-resistant subtype in spinal motor pools. MMP-9 therefore
provides a unifying hypothesis for class-, pool- and subtype-
specific aspects of selective motor neuron resistance to ALS.
Relevance to Non-SOD1-Linked Neurodegeneration
It will be important to determine whether MMP-9 is relevant to
the sporadic cases of ALS that make up 90% of all patients.
We identified MMP-9 based on selective resistance that is com-
mon tomousemodels and sporadic ALS patients. Moreover, our
data and others indicate that mSOD1 mice mirror to a remark-
able degree the precise pattern of selective neurodegenera-
tion—both in terms of motor pool and subtype—seen in patients
with sporadic disease. Recently, Brockington et al. (2013), using
laser capture microdissection from neurologically normal human346 Neuron 81, 333–348, January 22, 2014 ª2014 Elsevier Inc.postmortem samples, showed that MMP-9 levels are 2.5-fold
lower in oculomotor nucleus than in lumbar motor neurons.
Encouragingly, a recent human population study showed that
a polymorphism leading to higher Mmp9 promoter activity is
significantly associated with an increased risk of sporadic ALS
(He et al., 2013).
Our approach to ALS is of potential significance to neuro-
degenerative diseases affecting other neuronal classes. All
such diseases show a marked specificity that is reflected in
the clinical outcome. For example, in Parkinson’s disease dopa-
minergic neurons in the substantia nigra are most strongly
affected. Here, too, selective resistance is observed: mesostria-
tal neurons degenerate whereas mesolimbic and mesocortical
neurons aremore resistant (Damier et al., 1999; Liss and Roeper,
2008). Gene expression differences detected between these
populations have been shown to protect against the effects of
exogenous stressors (Chung et al., 2010). Blocking selective
vulnerability therefore might be a viable strategy in multiple ther-
apeutic contexts.
Overall, our study demonstrates how a precise understanding
of the biological diversity of neuronal subpopulations can lead
to significant new insights into the mechanisms involved in
neurological disease. Our molecular analysis further emphasizes
the remarkable extent of the differences and similarities between
different motor pools and subtypes. Importantly, it also allowed
us to manipulate the molecular makeup of FF motor neurons
postnatally so that they more closely resemble resistant S motor
neurons. The strong protection thereby conferred provides hope
that not only MMP-9 but also other genes with subtype-specific
expression might provide a basis for rational therapies in ALS
and other neurodegenerative diseases.EXPERIMENTAL PROCEDURES
Transgenic/Knockout Mice
For expression studies, ChAT-Cre (B6;129S6-Chattm1(cre)Lowl/J) and
ROSA-TdTomato reporter (B6;129S6-Gt(ROSA)26Sortm14(CAG-tdTomato)
Hze/J) mice were purchased from the Jackson Laboratory and crossed to
generate offspring whose motor neurons selectively express TdTomato.
Chodl-LacZmice were obtained from Lexicon Pharmaceuticals. For functional
studies, mice heterozygous for the mutant human SOD1G93A transgene
(B6.Cg-Tg(SOD1*G93A)1Gur/J) were crossed with mice heterozygous for an
MMP9 gene disruption (B6.FVB(Cg)-Mmp9tm1Tvu/J), both on a C57BL/6J
background. For all experiments, SOD1G93A;Mmp9/ mice were always
compared with their SOD1G93A;Mmp9+/+ or SOD1G93A;Mmp9+/ littermates.
End-stage of disease was defined as the age at which mSOD1 mice could
no longer right themselves for 30 s after being put on their side. All animal
work was performed in compliance with Columbia University IACUC
protocols.Microarray Analysis
Lumbosacral spinal cord and midbrain from three wild-type P7 male animals
were cryosectioned, mounted on RNase-free glass slides (Zeiss), fixed and
stained with 1% cresyl violet, and dehydrated prior to laser capture micro-
dissection using the PALM Microbeam System (Zeiss). From each animal,
200 DL, L5, and oculomotor motor neurons were collected directly into lysis
buffer. At least 1.5 ng of purified RNA was amplified in the WT-Ovation Pico
RNA Amplification System (Nugen) and hybridized to Affymetrix Mouse
Genome 430 2.0 Arrays. Gene ontology and pathway analysis was performed
using DAVID Bioinformatics Resources 6.7 (National Institute of Allergy and
Infectious Diseases, National Institutes of Health).
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The following primary antibodies were used: goat anti-ChAT 1:100 (Millipore),
rabbit anti-MMP-9 1:4,000 (Abcam), goat anti-MMP-9 1:2,000 (Sigma-
Aldrich), rabbit anti-GFP 1:1,000 (Invitrogen), mouse anti-NeuN 1:600
(Chemicon), chicken anti-beta-galactosidase 1:2,000 (Abcam), and rabbit
anti-phosphorylated EIF2a (Ser51) 1:150 (Cell Signaling Technology). To quan-
tify muscle denervation, consecutive longitudinal 40 mm cryosections of
muscles were stained for vesicular acetylcholine transporter (VAChT; Sigma)
and a-bungarotoxin (BTX; Invitrogen). The percentage of NMJ innervation
was determined by dividing the total number of areas of overlap between
VAChT and BTX signals (total number innervated endplates) by the number
of areas of BTX signal (total number of endplates).
Retrograde Labeling
Cholera toxin subunit B (CTB) conjugated to Alexa Fluor 488 or 555 was in-
jected into the Sol, TA, or IC muscles of wild-type mice at P5 or P40 or
Mmp9/ mice at P40. Animals were perfused and spinal cords collected
48–96 hr later. At that time, the injected muscle and surrounding muscles
were checked for fluorescence to assure specificity of injections.
Electrophysiological Measurements
Mice were anesthetized and two electrodes were placed on either side of
the sciatic nerve at a paraspinal site. The skin overlaying the TA was cut and
bipolar electrodes were inserted into the muscle. A controlled stimulation
was applied to the nerve to evoke contractions from the TA muscle in
10–50 mA increments from 50 mA.
AAV6 Viral Vectors
For i.c.v. injections, P1 pups were anesthetized and, using a 31 gauge 1/2 cc
insulin syringe (BD Ultra-Fine* II Short Needle Insulin Syringe, VWR), 2 ml of
virus was injected into the third ventricle. For i.m. injections, P4 pups were
anesthetized, the skin overlaying the TA muscles was opened, and 2 ml of
the AAV6.shMMP9 virus was injected using an insulin syringe. For the
AAV6.MMP9 i.m. administration, P4 pups were anesthetized and then 2 ml of
viral vector was injected into their TA, Sol, or extraocular muscles.
Pharmacological Inhibition
Wild-type or SOD1G93A mice (18–22 g) were anesthetized with isoflurane at
P50 and placed in a stereotaxic instrument, and a cannula was placed 1 mm
lateral and 1 mm caudal to bregma, at a depth of 2.5 mm. The animals were
allowed to recover for 5 days and then given daily injections into their cannulae
of MMP-9 Inhibitor I (2 mg per day dissolved in 10% DMSO; Calbiochem) or a
vehicle. The volume of all i.c.v. injections was 10 ml, using a 25 ml syringe (Ham-
ilton). Animals were perfused after 20 days of injections, at P75.ACCESSION NUMBERS
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